ETC
ACAD icon

Exchange Traded Concepts’s Acadia Pharmaceuticals ACAD Stock Holding History

Exchange Traded Concepts’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3K Sell
1,829
-66
-3% -$1.45K ﹤0.01% 1520
2026
Q1 		$42.2K Sell
1,895
-4,254
-69% -$102K ﹤0.01% 1450
2025
Q4 		$164K Buy
6,149
+3,795
+161% +$90.7K ﹤0.01% 1280
2025
Q3 		$50.2K Buy
2,354
+428
+22% +$10.1K ﹤0.01% 1296
2025
Q2 		$41.5K Buy
1,926
+150
+8% +$2.79K ﹤0.01% 1336
2025
Q1 		$29.5K Buy
+1,776
New +$32.3K ﹤0.01% 1240
2023
Q1 		– Sell
-5,240
Closed -$83.4K – 1135
2022
Q4 		$83.4K Buy
5,240
+1,303
+33% +$20.4K ﹤0.01% 781
2022
Q3 		$64K Buy
3,937
+1,228
+45% +$19.9K ﹤0.01% 803
2022
Q2 		$38K Buy
2,709
+2,077
+329% +$38.8K ﹤0.01% 944
2022
Q1 		$15K Buy
+632
New +$15.3K ﹤0.01% 1061
2021
Q2 		– Sell
-2,133
Closed -$55K – 1093
2021
Q1 		$55K Sell
2,133
-11,144
-84% -$491K ﹤0.01% 802
2020
Q4 		$710K Sell
13,277
-3,048
-19% -$151K 0.03% 279
2020
Q3 		$673K Buy
16,325
+15,596
+2,139% +$673K 0.04% 231
2020
Q2 		$35K Sell
729
-156
-18% -$7.49K 0.01% 559
2020
Q1 		$37K Buy
+885
New +$36.5K 0.02% 305

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Exchange Traded Concepts's ACAD Position: Q2 2026 in Review

Exchange Traded Concepts reduced its Acadia Pharmaceuticals (ACAD) stake by 3.5% in Q2 2026, selling an estimated $1.45K and leaving 1,829 shares worth $46.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1520.

Exchange Traded Concepts first reported a position in ACAD in Q1 2020 and has held it in 15 quarters since. The position peaked at $710K in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Exchange Traded Concepts held 1,829 shares of Acadia Pharmaceuticals worth $46.3K as of Q2 2026.
  • Exchange Traded Concepts sold 66 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.45K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #1520 holding.
  • Exchange Traded Concepts first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 15 quarters since.
  • Exchange Traded Concepts's Acadia Pharmaceuticals position peaked at $710K in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.